Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Phase II Study of Refametinib, a MEK inhibitor, as second-line treatment in advanced biliary
 tract adenocarcinoma
Refametinib will be administered orally at the starting dose of 50 mg twice daily on a
 continuous daily dosing schedule.

 Self-administration of refametinib tablets will take place on an outpatient basis. Patients
 experiencing dose-limiting toxicity attributed to study medication should have at least
 1-week treatment breaks inserted into the continuous daily dosing period as needed and/or may
 be interrupted or reduced depending on individual tolerability.
Inclusion Criteria:

 1. age ≥ 18

 2. histologically or cytologically confirmed adenocarcinoma of biliary tract

 3. unresectable or metastatic

 4. ECOG performance status of 0~2

 5. measurable lesion per RECIST 1.1 criteria

 6. adequate marrow, hepatic, renal functions

 7. normal range of cardiac function confirmed by echocardiogram within 1 year (LVEF ≥50)

 8. Child-Pugh Class A in case of liver cirrhosis

 9. One prior treatment of cytotoxic chemotherapy (including adjuvant treatment within 12
 months)

 10. Resolution of all acute toxic effects of any prior therapy to Common Toxicity Criteria
 for Adverse Events (CTCAE 4.03) ≤ grade 1.

 11. provision of a signed written informed consent

 Exclusion Criteria:

 1. History of cardiac disease

 2. Ongoing infection > Grade 2 according to NCI-CTCAE version 4.03. Hepatitis B is
 allowed if no active replication (defined as abnormal ALT >2xULN associated with HBV
 DNA >20,000 IU/mL) is present

 3. Severe co-morbid illness and/or active infections including active hepatitis C and
 human immunodeficiency virus (HIV) infection

 4. History of interstitial lung disease (ILD).

 5. Any cancer curatively treated < 3 years prior to study entry, except cervical
 carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors
 (Staging: Ta, Tis and T1).

 6. Renal failure requiring hemo- or peritoneal dialysis.

 7. Clinically significant GI bleeding (CTCAE 4.03 grade 3 or higher) within 30 days prior
 to start of screening

 8. Thrombotic or embolic events such as cerebrovascular accident (including transient
 ischemic attacks) within 6 months prior to start of screening.

 9. History of organ allograft, cornea transplantation will be allowed

 10. Active CNS metastases not controllable with radiotherapy or corticosteroids

 11. Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk
 factor for RVO or CSR.

 12. Known history of hypersensitivity to study drugs

 13. Any condition that was unstable or which could jeopardize the safety of the patient
 and his/her compliance in the study

 14. Non-healing wound, ulcer, or bone fracture.

 15. Patients with seizure disorder requiring medication.

 16. Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4 should be stopped 2
 weeks before start of screening (see Appendix 1).

 17. Acute steroid therapy or taper for any purpose (chronic steroid therapy is acceptable
 provided that the dose is stable for 1 month before start of screening and
 thereafter).

 18. Substance abuse, medical, psychological or social conditions that may interfere with
 the patient's participation in the study or evaluation of the study results.

 19. Pregnant or lactating women. Women of childbearing potential not employing adequate
 contraception. Women of childbearing potential must have a negative serum pregnancy
 test performed within 7 days prior to start of study treatment and a negative result
 must be documented before first dose of study drug.